This trial is active, not recruiting.

Conditions liver fibrosis, hepatic fibrosis, liver cirrhosis, hepatic cirrhosis
Treatments idn-6556, placebo
Phase phase 2
Sponsor Conatus Pharmaceuticals Inc.
Start date May 2014
End date February 2018
Trial size 60 participants
Trial identifier NCT02138253, IDN-6556-07


This is a double-blind, multicenter study involving patients with chronic HCV infection who had a liver transplantation; developed HCV-related liver fibrosis and/or incomplete cirrhosis; achieved a sustained virologic response (SVR) following anti-HCV therapy; but still have fibrosis and/or incomplete cirrhosis on liver biopsy to see if treatment with IDN-6556 is better than placebo in reversing or stopping the progression of the damage to the new liver caused by HCV.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
IDN-6556 25 mg BID
idn-6556 emricasan
(Placebo Comparator)
Placebo BID
Placebo control

Primary Outcomes

Ishak Fibrosis Score
time frame: 24 months

Secondary Outcomes

Necro-inflammatory sub-score of the modified Histological Activity Index
time frame: 24 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and able to understand and willing to comply with the requirements of the study - History of orthotopic liver transplantation for HCV-induced liver disease - Diagnosis of HCV infection (HCV-RNA detectable in serum) and liver fibrosis and/or incomplete cirrhosis status post liver transplantation, and achieved a sustained virologic response (SVR) with anti-viral HCV treatment within 18 months of Day 1 - Liver fibrosis on liver histology as read by central histopathologist of Ishak F2 to F6 within three months of Day 1 (Up to 15 subjects with an Ishak score of F6 can be enrolled) - Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from Screening to one month after the last dose of study drug Exclusion Criteria: - Known infection with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV) - History of renal transplant and/or severe renal impairment defined as eGFR (estimated glomerular filtration rate) of less than 30 mL/min/1.73 m2 - Evidence of tumor burden >Milan criteria, or evidence of micro- or macrovascular invasion in explanted liver - Hepatocellular carcinoma (HCC) at entry into the study - Concurrent sirolimus (rapamycin) use - History or presence of clinically concerning cardiac arrhythmias, or prolongation of Screening (pre-treatment) QT or QTc interval of > 480 milliseconds (msec) - Subjects with diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA) - If female: known pregnancy, positive urine or serum pregnancy test, or lactating/breastfeeding

Additional Information

Official title A Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects Who Had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following Anti-HCV Therapy
Description There are data to suggest that with eradication of the HCV virus, improvements in liver fibrosis can be seen in the post-transplant population. However, amelioration of inflammatory activity, and deceleration of fibrosis progression is a gradual process over the course of many years. This placebo-controlled study is designed to evaluate the effects of IDN-6556, compared to placebo, on markers of apoptosis and inflammation, and liver histology.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by Conatus Pharmaceuticals Inc..